`
`Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
`
`U.S. Food and Drug Administration
`Protecting and Promoting Your Health
`
`Orange Book: Approved Drug Products
`with Therapeutic Equivalence Evaluations
`
`f SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP?
`U=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS PRODUCT.CFM?APPL_TYPE=N&APPL_NO=203971
`
`WV TWEET(HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE
`EVALUATIONS&URL=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_ TYPE=N&APPL_NO=203971
`
`+ &
`
`EMAIL (MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE
`EVALUATIONS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=203971
`
`Home(default.cfm?resetfields=1) | Back to Search Results
`
`Product Details for NDA 203971
`
`XOFIGO (RADIUM RA-223 DICHLORIDE)
`162mCi/6ML (27mCi/ML)
`
`Marketing Status: Prescription
`
`Active Ingredient: RADIUM RA-223 DICHLORIDE
`Proprietary Name: XOFIGO
`Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS
`Strength: 162mCi/6ML (27mCi/ML)
`Reference Listed Drug: Yes
`TE Code:
`Application Number: N203971
`Product Number: 001
`Approval Date: May 15, 2013
`Applicant Holder Full Name: BAYER HEALTHCARE PHARMACEUTICALS INC
`Marketing Status: Prescription
`Patent and Exclusivity Information
`(patent _info.cfm?
`
`
`http://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&Appl_No=203971
`
`1/1
`
`JANSSEN EXHIBIT 2106
`Amerigen v. Janssen IPR2016-00286
`
`JANSSEN EXHIBIT 2106
`Amerigen v. Janssen IPR2016-00286
`
`